Impact of complete revascularization in coronary artery bypass grafting for ischemic cardiomyopathy

In patients with ischemic cardiomyopathy, coronary artery bypass grafting ensures better survival than medical therapy. However, the long-term clinical impact of complete revascularization remains unclear. This observational study aimed to evaluate the effects of complete revascularization on long-t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JTCVS open 2023-09, Vol.15, p.211-219
Hauptverfasser: Nakae, Masaro, Kainuma, Satoshi, Toda, Koichi, Yoshikawa, Yasushi, Hata, Hiroki, Yoshioka, Daisuke, Kawamura, Takuji, Kawamura, Ai, Kashiyama, Noriyuki, Ueno, Takayoshi, Kuratani, Toru, Kondoh, Haruhiko, Hiraoka, Arudo, Sakaguchi, Taichi, Yoshitaka, Hidenori, Shirakawa, Yukitoshi, Takahashi, Toshiki, Sakaki, Masayuki, Masai, Takafumi, Komukai, Sho, Kitamura, Tetsuhisa, Hirayama, Atsushi, Shimomura, Yoshimitsu, Miyagawa, Shigeru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In patients with ischemic cardiomyopathy, coronary artery bypass grafting ensures better survival than medical therapy. However, the long-term clinical impact of complete revascularization remains unclear. This observational study aimed to evaluate the effects of complete revascularization on long-term survival and left ventricular functional recovery in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting. We retrospectively reviewed outcomes of 498 patients with ischemic cardiomyopathy who underwent complete (n = 386) or incomplete (n = 112) myocardial revascularization between 1993 and 2015. The baseline characteristics were adjusted using inverse probability of treatment weighting to reduce the impact of treatment bias and potential confounding. The mean follow-up duration was 77.2 ± 42.8 months in survivors. The overall 5-year survival rate (complete revascularization, 72.5% vs incomplete revascularization, 57.9%, P = .03) and freedom from all-cause death and/or readmission due to heart failure (54.5% vs 40.1%, P = .007) were significantly greater in patients with complete revascularization than those with incomplete revascularization. After adjustments using inverse probability of treatment weighting, the complete revascularization group demonstrated a lower risk of all-cause death (hazard ratio, 0.61; 95% confidence interval, 0.43-0.86; P = .005) and composite adverse events (hazard ratio, 0.59; 95% confidence interval, 0.44-0.79; P 
ISSN:2666-2736
2666-2736
DOI:10.1016/j.xjon.2023.04.008